{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:03:39Z","timestamp":1781071419218,"version":"3.54.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA0918500"],"award-info":[{"award-number":["2024YFA0918500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["25ZXWCSY00260"],"award-info":[{"award-number":["25ZXWCSY00260"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD73 is a key enzyme in the adenosine-mediated immunosuppressive pathway and represents an attractive target for cancer immunotherapy. Here, we aimed to develop novel anti-CD73 antibodies with dual mechanisms of action by simultaneously inhibiting enzymatic activity and promoting receptor internalization to more effectively disrupt the adenosine barrier within the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two monoclonal antibodies, CR201 and CR202, were generated and characterized for cross-species reactivity, inhibition of both membrane-bound and soluble CD73 enzymatic activity, and domain-specific epitope recognition. Functional assays were performed to evaluate reversal of AMP-mediated T-cell suppression, restoration of IFN-\u03b3 secretion, and induction of CD73 internalization.\n                      <jats:italic>In vivo<\/jats:italic>\n                      efficacy was assessed using an A375 melanoma xenograft model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CR201 and CR202 specifically bound human and cynomolgus CD73 and recognized distinct structural domains, with CR202 targeting the N-terminal domain and CR201 binding the C-terminal domain. Functionally, CR202 demonstrated greater potency against membrane-bound CD73, whereas CR201 achieved complete inhibition of soluble CD73 activity. Both antibodies effectively restored T-cell proliferation and IFN-\u03b3 production and promoted internalization of surface CD73.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , treatment with either antibody significantly suppressed tumor growth without observable toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CR201 and CR202 are domain-specific, dual-mechanism anti-CD73 antibodies that integrate potent enzymatic blockade with receptor internalization, thereby enhancing antitumor immune responses. These findings highlight the therapeutic potential of targeting distinct functional domains of CD73 to overcome adenosine-mediated immunosuppression in cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1861537","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:37:08Z","timestamp":1781069828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University","place":["Tianjin, China"]},{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Yuan","sequence":"additional","affiliation":[{"name":"School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Pan","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Gu","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Hu","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Qu","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguo","family":"Gu","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Mu","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbo","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ario","family":"de Marco","sequence":"additional","affiliation":[{"name":"Laboratory for Environmental and Life Sciences, University of Nova Gorica","place":["Nova Gorica, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshan","family":"Zhou","sequence":"additional","affiliation":[{"name":"China Resources Biopharmaceutical Company Limited","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0144-8","article-title":"PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transd Targ Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":":75","DOI":"10.1186\/s40364-025-00784-0","article-title":"The progress and prospects of targeting the adenosine pathway in cancer immunotherapy","volume":"13","author":"Yang","year":"2025","journal-title":"biomark Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1544","article-title":"CD73: A novel target for cancer immunotherapy","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":":109738","DOI":"10.1016\/j.isci.2024.109738","article-title":"GRHL2 suppression of NT5E \/ CD73 in breast cancer cells modulates CD73-mediated adenosine production and T cell recruitment","volume":"27","author":"Coban","year":"2024","journal-title":"Iscience"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a multi-signalling guardian angel in human diseases : When, where and how does it exert its protective effects","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.121.000445","article-title":"International Union of Basic and Clinical Pharmacology. CXII: Adenosine receptors: A further update","volume":"74","author":"IJzerman","year":"2022","journal-title":"Pharmacol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-366781","article-title":"Alterations in the adenosine metabolism and CD39\/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID","volume":"119","author":"Sauer","year":"2012","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1147782","article-title":"CD73, a significant protein in liver diseases","volume":"10","author":"Shi","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","article-title":"Cellular function and molecular structure of ecto-nucleotidases","volume":"8","author":"Zimmermann","year":"2012","journal-title":"Purinergic Signal"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00813","article-title":"Controlling the immune suppressor: Transcription factors and microRNAs regulating CD73\/NT5E","volume":"9","author":"Kordass","year":"2018","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26525","article-title":"CD73 (Ecto-5\u2019Nucleotidase) hepatocyte levels differ across mouse strains and contribute to Mallory-Denk body formation","volume":"58","author":"Snider","year":"2013","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201200426","article-title":"Crystal structure of a soluble form of human CD73 with ecto-5\u2019Nucleotidase activity","volume":"13","author":"Heuts","year":"2012","journal-title":"ChemBioChem"},{"key":"B15","doi-asserted-by":"publisher","first-page":":100092","DOI":"10.1016\/j.pharmr.2025.100092","article-title":"Targeting the adenosinergic axis in cancer immunotherapy: Insights into A2A and A2B receptors and novel clinical combination strategies","volume":"77","author":"Rodriguez-Pampin","year":"2025","journal-title":"Pharmacol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2023.03.005","article-title":"CD73 in glioblastoma: Where are we now and what are the future directions","volume":"256","author":"Gelsleichter","year":"2023","journal-title":"Immunol Lett"},{"key":"B17","doi-asserted-by":"publisher","first-page":":e2206335","DOI":"10.1002\/advs.202206335","article-title":"CD73, a promising therapeutic target of diclofenac, promotes metastasis of pancreatic cancer through a nucleotidase independent mechanism","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00508","article-title":"CD73's potential as an immunotherapy target in gastrointestinal cancers","volume":"11","author":"Harvey","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":":100165","DOI":"10.1016\/j.jhepr.2020.100165","article-title":"Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities","volume":"2","author":"Wang","year":"2020","journal-title":"Jhep Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":":11759","DOI":"10.3390\/ijms241411759","article-title":"The clinical significance of CD73 in cancer","volume":"24","author":"Bach","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.87440","article-title":"Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion","volume":"20","author":"Lian","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":":e2404709121","DOI":"10.1073\/pnas.2404709121","article-title":"CD73 promotes non-small cell lung cancer metastasis by regulating Axl signaling independent of GAS6","volume":"121","author":"Zhu","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","first-page":":7685","DOI":"10.3390\/ijms22147685","article-title":"Adenosine and inflammation: Here, there and everywhere","volume":"22","author":"Pasquini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3569","article-title":"CD73 is associated with poor prognosis in high-grade serous ovarian cancer","volume":"75","author":"Turcotte","year":"2015","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: An emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0107","article-title":"A novel antagonistic CD73 antibody for inhibition of the immunosuppressive adenosine pathway","volume":"20","author":"Wurm","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":":44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012534","article-title":"Evaluation of nanobody - based biologics targeting purinergic checkpoints in tumor models in vivo","volume":"13","author":"Demeules","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2020","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":":348","DOI":"10.1007\/s00432-024-05869-1","article-title":"Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma","volume":"150","author":"Sun","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.06.017","article-title":"NSGO-OV-UMB1\/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer","volume":"188","author":"Mirza","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.055508","article-title":"Assessing the impact of CD73 inhibition on overcoming anti-EGFR resistance in glioma cells","volume":"33","author":"Silva","year":"2025","journal-title":"Oncol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab plus oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":":116028","DOI":"10.1016\/j.ejmech.2023.116028","article-title":"Small molecular CD73 inhibitors: Recent progress and future perspectives","volume":"264","author":"Ge","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01044","article-title":"Targeting metabolism of extracellular nucleotides via inhibition of ectonucleotidases CD73 and CD39","volume":"63","author":"Jeffrey","year":"2020","journal-title":"J Med Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0802","article-title":"Targeting CD73 with AB680 (Quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity","volume":"21","author":"Piovesan","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":":e1208875","DOI":"10.1080\/2162402X.2016.1208875","article-title":"Targeting CD73 in the tumor microenvironment with MEDI9447","volume":"5","author":"Hay","year":"2016","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","first-page":":2505","DOI":"10.1200\/JCO.2019.37.15_suppl.2505","article-title":"Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers","volume":"37","author":"Luke","year":"2019","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02242-5","article-title":"Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid Malignancies: a phase I, open-label study","volume":"27","author":"Kondo","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":":CT503","DOI":"10.1158\/1538-7445.am2022-ct503","article-title":"A phase I\/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and\/or taminadenant in patients (pts) with advanced Malignancies","volume":"82","author":"Fu","year":"2022","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"749\u2013773","DOI":"10.1002\/med.70029","article-title":"Medicinal chemistry strategies for the development of CD73 inhibitors in cancer immunotherapy","volume":"46","author":"Cui","year":"2026","journal-title":"Med Res Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.12.258","article-title":"Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy","volume":"229","author":"Zhou","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1143182","article-title":"Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action","volume":"8","author":"Geoghegan","year":"2016","journal-title":"Mabs"},{"key":"B46","doi-asserted-by":"publisher","first-page":":e142843","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","first-page":":e006837","DOI":"10.1136\/jitc-2023-006837","article-title":"Bispecific antibody CD73xEGFR more selectively inhibits the CD73 \/ adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR","volume":"11","author":"Ploeg","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":":LB131","DOI":"10.1158\/1538-7445.AM2024-LB131","article-title":"CBO421 , a novel drug Fc-conjugate , inhibits the enzymatic activity of CD73 and triggers CD73 internalization","volume":"84","author":"Abelovski","year":"2024","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":":e004554","DOI":"10.1136\/jitc-2022-004554","article-title":"Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity","volume":"10","author":"Gammelgaard","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B50","article-title":"Anti-CD73 antibodies and uses thereof. International patent application WO2018137598A1","author":"Wang","year":"2018"},{"key":"B51","doi-asserted-by":"publisher","first-page":":e001689","DOI":"10.1136\/jitc-2020-001689","article-title":"Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy","volume":"8","author":"Turiello","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:37:10Z","timestamp":1781069830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1861537"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1861537","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1861537"}}